30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: Seikagaku

(for fiscal 3Q13, ended 12/31/13)

  • ¥7,717MM (~US $75.8MM), +4%


Highlights pertain to trailing 9 months.

  • Growth attributed to higher sales volume of Gel-One, impact of yen depreciation
  • Domestic ARTZ growth slowing in the face of a softening market
  • U.S. sales of SUPARTZ fell only slightly
  • Confirmed victory in patent infringement suit brought by Genzyme (Genzyme withdrew its appeal)